CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 10 of 10

Some of the metrics are blocked by your
consent settings
Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial
(Springer Science and Business Media LLC, 2025-12-07)
Linmar Rodríguez-Guilarte
;
Constanza Méndez
;
Antonia Reyes
;
Mariana Rios
;
Francisca Román
Scopus© Citations 2 1
Some of the metrics are blocked by your
consent settings
A prospective, multicenter study of invasive fungal disease caused by molds in children and adults in Chile
(Public Library of Science (PLoS), 2025-09-08)
Ricardo Rabagliati
;
Dona Benadof
;
THOMPSON MOYA, LUIS ADALBERTO
;
Patricia Garcia
;
Tamara Gonzalez
Background Invasive mold diseases (IMDs) are a severe complication of immunocompromised subjects and an emerging problem among severely ill, apparently immunocompetent patients. The aim of this study was to describe the epidemiological and clinical features of IMDs in Chile.Methods Prospective study of IMD cases in children and adults from 11 reference hospitals in Chile from May 2019 to May 2021.Results One hundred seventy-six cases were included, 135 in adults and 41 in children, with an overall incidence of 0.4/1,000 admissions. The median age was 10.5 years in children and 56.6 years in adults, with male gender predominance in adults (61.5% versus 41.5%, p = 0.03). Immunosuppression was the most common condition in both children and adults. However, cancer, neutropenia, and hematopoietic cell transplantation were significantly more frequent in the pediatric group. In contrast, diabetes, viral pneumonia, chronic kidney disease, and chronic obstructive pulmonary disease were significantly more frequent among adult patients. Regarding the diagnostic category, 30.1% of cases were proven, 55.7% probable and 14.2% possible. Aspergillosis was the most frequent IMD diagnosed in 75.5% of cases, followed by fusariosis in children and mucormycosis in adults. Viral pneumonia was associated in 40.3% of cases, mainly COVID-19, with aspergillosis in 87.3%. No triazole resistance was observed in Aspergillus spp.. Antifungals were prescribed in 97.2% of the patients: voriconazole 61.4%, liposomal amphotericin 20.5%, combination antifungals 11.1%, and others 6.4%. Overall survival was 68.7%, 61.4%, and 51.7% at 30, 90 and 180 days, respectively.Discussion This is the most extensive study of IMDs in Chile, evidencing an incidence of 0.4 per 1,000 admissions, with aspergillosis being the most frequent infection. Nearly 40% of cases were associated with respiratory viruses, accounting for the impact of COVID-19. Despite almost all patients starting antifungal therapy, the survival rate was poor. It is advisable to start a surveillance program of IMDs in Chile and verify the absence of azole resistance of Aspergillus spp.
3
Some of the metrics are blocked by your
consent settings
Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study
(2024)
Marcela Ferrés
;
Constanza Martínez-Valdebenito
;
Carolina Henriquez
;
Claudia Marco
;
Jenniffer Angulo
10Scopus© Citations 29
Some of the metrics are blocked by your
consent settings
High-Dose Intravenous Methylprednisolone for Hantavirus Cardiopulmonary Syndrome in Chile: A Double-Blind, Randomized Controlled Clinical Trial
(2013)
Pablo A. Vial
;
Francisca Valdivieso
;
Marcela Ferres
;
Raul Riquelme
;
M. Luisa Rioseco
4Scopus© Citations 71
Some of the metrics are blocked by your
consent settings
Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile
(2023)
Nicole Le Corre
;
Katia Abarca
;
Patricio Astudillo
;
Marcela Potin
;
Sofía López
<jats:p>During the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac® in children and adolescents between 3- and 17-years-old in a multicenter study in Chile with two vaccine doses in a 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) were registered throughout the study. In the safety subgroup, AEs were recorded 28 days after each dose. COVID-19 surveillance was performed throughout the study. A total of 1139 individuals received the first and 1102 the second dose of CoronaVac®; 835 were in the safety subgroup. The first dose showed the highest number of AEs: up to 22.2% of participants reported any local and 17.1% systemic AE. AEs were more frequent in adolescents after the first dose, were transient, and mainly mild. Pain at the inoculation site was the most frequent AE for all ages. Fever was the most frequent systemic AE for 3–5 years old and headache in 6–17 years old. No SAEs or AESIs related to vaccination occurred. Most of the COVID-19 cases were mild and managed as outpatients. CoronaVac® was safe and well tolerated in children and adolescents, with different safety patterns according to age.</jats:p>
Scopus© Citations 3 3
Some of the metrics are blocked by your
consent settings
Proteinuria in Hantavirus Cardiopulmonary Syndrome: A Frequent Finding Linked To Mortality
(2021)
LOPEZ HERNANDEZ, RENE RAMON
;
Gregory Mertz
;
GRAF SANTOS, JERÓNIMO
;
Mauricio Espinoza
;
Marcela Ferrés
27Scopus© Citations 4
Some of the metrics are blocked by your
consent settings
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children
(2022)
Jorge A. Soto
;
Felipe Melo-González
;
Cristián Gutierrez-Vera
;
Bárbara M. Schultz
;
Roslye V. Berríos-Rojas
<jats:p>This work evaluated the immune response induced by two doses of CoronaVac separated by 4 weeks in healthy children and adolescents in Chile. To date, few studies have described the effects of CoronaVac in the pediatric population.</jats:p>
1Scopus© Citations 20 16
Some of the metrics are blocked by your
consent settings
A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus
(2015)
VIAL CLARO, PABLO AGUSTIN
;
Francisca Valdivieso
;
Mario Calvo
;
M Luisa Rioseco
;
Raul Riquelme
<jats:sec><jats:title>Background</jats:title><jats:p> In Chile, Andes virus (ANDV) is the sole aetiological agent of hantavirus cardiopulmonary syndrome (HCPS) with mean annual incidence of 55 cases, 32% case fatality rate (CFR) and no specific treatment. Neutralizing antibody (NAb) titres at hospital admission correlate inversely with HCPS severity. We designed an open trial to explore safety and efficacy and evaluate pharmacokinetics of immune plasma as a treatment strategy for this disease. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> We performed plasmapheresis on donors at least 6 months after HCPS and measured NAb titres through a focus-reduction neutralization test. Subjects admitted to 10 study sites with suspected/confirmed HCPS were eligible for treatment with immune plasma by intravenous infusion at an ANDV NAb dose of 5,000 U/kg. HCPS was confirmed through immunoglobulin M serology or reverse transcriptase-PCR. The main outcome was mortality within 30 days. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> From 2008–2012, we enrolled and treated 32 cases and confirmed HCPS in 29. CFR of hantavirus plasma-treated cases was 4/29 (14%); CFR of non-treated cases in the same period in Chile was 63/199 (32%; P=0.049, OR=0.35, CI=0.12, 0.99); CFR of non-treated cases at the same study sites between 2005–2012 was 18/66 (27%; ( P=0.15, OR=0.43, CI=0.14, 1.34) and CFR in a previous methylprednisolone treatment study was 20/60 (33%; P=0.052, OR=0.32, CI=0.10, 1.00). We detected no serious adverse events associated to plasma infusion. Plasma NAb titres reached in recipients were variable and viral load remained stable. </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Human ANDV immune plasma infusion appears safe for HCPS. We observed a decrease in CFR in treated cases with borderline significance that will require further studies for confirmation. </jats:p></jats:sec>
Scopus© Citations 56 2
Some of the metrics are blocked by your
consent settings
Person-to-Person Household and Nosocomial Transmission of Andes Hantavirus, Southern Chile, 2011
(2014)
Constanza Martinez-Valdebenito
;
Mario Calvo
;
VIAL COX, MARIA CECILIA
;
Rita Mansilla
;
Claudia Marco
22Scopus© Citations 90
Some of the metrics are blocked by your
consent settings
Platelet Count in Patients with Mild Disease at Admission is Associated with Progression to Severe Hantavirus Cardiopulmonary Syndrome
(2019)
LOPEZ HERNANDEZ, RENE RAMON
;
Mario Calvo
;
VIAL COX, MARIA CECILIA
;
Marcela Ferrés
;
GRAF SANTOS, JERÓNIMO
<jats:p>Background: Hantavirus cardiopulmonary syndrome (HCPS) has a mortality up to 35–40% and its treatment is mainly supportive. A variable to predict progression from mild to severe disease is unavailable. This study was performed in patients with documented infection by Andes orthohantavirus, and the aim was to find a simple variable to predict progression to moderate/severe HCPS in patients with mild disease at admission. Methods: We performed a retrospective analysis of 175 patients between 2001 and 2018. Patients were categorized into mild, moderate, and severe disease according to organ failure and advanced support need at hospital admission (e.g., mechanical ventilation, vasopressors). Progression to moderate/severe disease was defined accordingly. Clinical and laboratory variables associated with progression were explored. Results: Forty patients with mild disease were identified; 14 of them progressed to moderate/severe disease. Only platelet count was different between those who progressed versus those that did not (37 (34–58) vs. 83 (64–177) K/mm3, p < 0.001). A ROC curve analysis showed an AUC = 0.889 (0.78–1.0) p < 0.001, with a platelet count greater than 115K /mm3 ruling out progression to moderate/severe disease. Conclusions: In patients with mild disease at presentation, platelet count could help to define priority of evacuation to tertiary care centers.</jats:p>
Scopus© Citations 10 4

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results